Nygren PJ, Bouhlal JOV, Jokinen E, Forstén S, Laajala E, Dias DAA, Adnan Awad S, Ianevski A, Klievink J, Lähteenmäki H, Kuusanmäki H, Myllymäki M, Kasanen T, Saeed K, Lee DA, Flagship I, Hjorth-Hansen H, Aittokallio T, Dufva O, Mustjoki S(2025) High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia Blood(in press) DOI 10.1182/blood.2024025286, PubMed 39792962
Pölöske D, Sorger H, Schönbichler A, de Araujo ED, Neubauer HA, Orlova A, Timonen SH, Abdallah DI, Ianevski A, Kuusanmäki H, Surbek M, Heyes E, Eder T, Wagner C, Suske T, Metzelder ML, Bergmann M, Dahlhoff M, Grebien F, Fleck R, Pirker C, Berger W, Hadzijusufovic E, Sperr WR, Kenner Let al.(2024) Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma Hemasphere, 8(12), e70001 DOI 10.1002/hem3.70001, PubMed 39619245
Tanoli Z, Schulman A, Aittokallio T(2024) Validation guidelines for drug-target prediction methods Expert Opin Drug Discov, 20(1), 31-45 DOI 10.1080/17460441.2024.2430955, PubMed 39568436
